Will active surveillance for clinically localized prostate cancer survive in the era of individualized medicine?
The challenge for the next few years will be to individualize prostate cancer treatment and to determine whether or not a cancer will be lethal based on molecular characteristics at the time of diagnosis. In this view, the need for active treatment would represent a failure of any conservative approach.
Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
Giorgio
G
Gandaglia
Department of Urology, University of Bern, Inselspital, Bern, Switzerland.
Gianluca
G
Giannarini
Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
Nazareno
N
Suardi
Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
Francesco
F
Montorsi
Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: briganti.alberto@hsr.it.
Alberto
A
Briganti
D000230:Adenocarcinoma / Q000175:diagnosis*; D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000175:diagnosis*; D051517:Digital Rectal Examination; D006801:Humans; D008297:Male; D011467:Prostate / Q000473:pathology*; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000175:diagnosis*; D012983:Soft Tissue Neoplasms / Q000175:diagnosis*; D057832:Watchful Waiting / Q000379:methods*
D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen